clinical trial · NCT04515836
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago·phase2·recruiting·n = 56
MesotheliomaHomologous Recombination DeficiencyOlaparib
brief summary
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
started
Feb 19, 2021
primary completion
Apr 15, 2028
completion
Apr 15, 2028
last updated
May 6, 2025
official title
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol